[go: up one dir, main page]

MX2017000595A - Anticuerpos anti-influenza b neutralizantes y usos de los mismos. - Google Patents

Anticuerpos anti-influenza b neutralizantes y usos de los mismos.

Info

Publication number
MX2017000595A
MX2017000595A MX2017000595A MX2017000595A MX2017000595A MX 2017000595 A MX2017000595 A MX 2017000595A MX 2017000595 A MX2017000595 A MX 2017000595A MX 2017000595 A MX2017000595 A MX 2017000595A MX 2017000595 A MX2017000595 A MX 2017000595A
Authority
MX
Mexico
Prior art keywords
influenza
virus
same
neutralizing antibodies
hemagglutinin
Prior art date
Application number
MX2017000595A
Other languages
English (en)
Other versions
MX392761B (es
Inventor
BENJAMIN Ebony
Kallewaard-Lelay Nicole
Mary Mcauliffe Josephine
Wachter Leslie
Yuan Andy
Zhu Qing
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2017000595A publication Critical patent/MX2017000595A/es
Publication of MX392761B publication Critical patent/MX392761B/es

Links

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a anticuerpos y fragmentos de unión a antígeno de los mismos que pueden unirse a la hemaglutinina (HA) del virus de influenza B y neutralizar virus de influenza B en dos linajes distintos desde un punto de vista filogenético. En una modalidad, el anticuerpo o fragmento de unión a antígeno puede unirse a la hemaglutinina del virus de influenza B y neutralizar virus de influenza B en linajes Yamagata y Victoria.
MX2017000595A 2014-07-15 2015-07-14 Anticuerpos anti-influenza b neutralizantes y usos de los mismos. MX392761B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462024804P 2014-07-15 2014-07-15
PCT/US2015/040385 WO2016011035A2 (en) 2014-07-15 2015-07-14 Neutralizing anti-influenza b antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2017000595A true MX2017000595A (es) 2017-10-12
MX392761B MX392761B (es) 2025-03-21

Family

ID=55079157

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017000595A MX392761B (es) 2014-07-15 2015-07-14 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
MX2022006558A MX2022006558A (es) 2014-07-15 2017-01-13 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
MX2022006561A MX2022006561A (es) 2014-07-15 2017-01-13 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022006558A MX2022006558A (es) 2014-07-15 2017-01-13 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
MX2022006561A MX2022006561A (es) 2014-07-15 2017-01-13 Anticuerpos anti-influenza b neutralizantes y usos de los mismos.

Country Status (10)

Country Link
US (6) US10294292B2 (es)
EP (1) EP3169407A4 (es)
JP (4) JP6837434B2 (es)
CN (4) CN113563462B (es)
AU (3) AU2015289805B2 (es)
BR (1) BR112017000640A2 (es)
CA (1) CA2954780A1 (es)
MX (3) MX392761B (es)
RU (2) RU2711932C2 (es)
WO (1) WO2016011035A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102501920B1 (ko) * 2013-10-02 2023-02-20 메디뮨 엘엘씨 중화 항-인플루엔자 a 항체 및 이의 용도
MX392761B (es) 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
JP6867306B2 (ja) 2015-06-01 2021-04-28 メディミューン，エルエルシー 中和抗インフルエンザ結合分子及びその使用
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法
PH12022550963A1 (en) * 2019-10-28 2023-09-25 Regeneron Pharma Anti-hemagglutinin antibodies and methods of use thereof
CN112048006B (zh) * 2020-09-08 2021-04-27 扬州大学 一种替代中和效力测定的elisa方法及其应用
US20250320279A1 (en) * 2021-11-30 2025-10-16 Sab, Llc Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof
CN118420751B (zh) * 2022-07-09 2025-04-08 东莞市朋志生物科技有限公司 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6027459A (en) 1996-12-06 2000-02-22 Abbott Laboratories Method and apparatus for obtaining blood for diagnostic tests
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
JP4528989B2 (ja) * 1999-03-31 2010-08-25 学校法人慶應義塾 インフルエンザウイルス・ヘマグルチニン結合性ペプチド
AU2001234125A1 (en) 2000-02-22 2001-09-03 Medical And Biological Laboratories Co., Ltd. Antibody library
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
CN1671741A (zh) 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
WO2004007667A2 (en) 2002-07-11 2004-01-22 The General Hospital Corporation Polynucleotide and polypeptide fat metabolism regulators and uses thereof
ES2562177T3 (es) 2002-09-27 2016-03-02 Xencor Inc. Variantes de Fc optimizadas y métodos para su generación
RU2366662C2 (ru) 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
CN1867355A (zh) 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 包含诱导粘膜免疫的佐剂的新型疫苗
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005056759A2 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
NZ596322A (en) 2006-01-17 2013-02-22 Synthon Biopharmaceuticals Bv Compositions and methods for humanization and optimization of N-glycans in duckweed plants
CA2647380A1 (en) 2006-03-21 2007-09-27 David T. Weaver Methods for humanizing antibodies and humanized antibodies made thereby
US7615220B2 (en) 2006-04-07 2009-11-10 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-18 receptor
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
JP5161882B2 (ja) 2006-09-07 2013-03-13 クルセル ホランド ベー ヴェー インフルエンザウイルスｈ５ｎ１を中和しうるヒト結合性分子およびその使用
US7605237B2 (en) 2006-10-02 2009-10-20 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US9340603B2 (en) 2008-07-25 2016-05-17 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
AU2011344126B2 (en) 2010-12-13 2016-11-10 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
EA027054B1 (ru) * 2011-07-14 2017-06-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
LT3418300T (lt) 2011-07-18 2021-01-11 Institute For Research In Biomedicine Neutralizuojantys antikūnai prieš gripo virusą a ir jų panaudojimas
CN108164602A (zh) 2011-09-20 2018-06-15 西奈山医学院 流感病毒疫苗及其应用
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
EP2776061B1 (en) * 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
EP2793945B1 (en) * 2011-12-05 2018-08-15 Trellis Bioscience, LLC Antibodies useful in passive influenza immunization
WO2013132007A1 (en) * 2012-03-08 2013-09-12 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
ES2701746T3 (es) 2012-11-13 2019-02-25 Hoffmann La Roche Anticuerpos antihemaglutinina y procedimientos de uso
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
RU2536956C1 (ru) 2013-08-05 2014-12-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а
KR102501920B1 (ko) 2013-10-02 2023-02-20 메디뮨 엘엘씨 중화 항-인플루엔자 a 항체 및 이의 용도
MX392761B (es) 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
JP6867306B2 (ja) 2015-06-01 2021-04-28 メディミューン，エルエルシー 中和抗インフルエンザ結合分子及びその使用
CN116271017A (zh) 2016-01-13 2023-06-23 免疫医疗有限责任公司 治疗甲型流感的方法
WO2017147248A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus

Also Published As

Publication number Publication date
CN113173990A (zh) 2021-07-27
US20190233504A1 (en) 2019-08-01
MX2022006561A (es) 2022-07-11
RU2020100073A (ru) 2020-03-03
US12325740B2 (en) 2025-06-10
JP2021074013A (ja) 2021-05-20
CN113563462A (zh) 2021-10-29
US11174304B2 (en) 2021-11-16
RU2020100073A3 (es) 2020-06-10
CN113173990B (zh) 2024-10-29
BR112017000640A2 (pt) 2017-11-14
CN106573154A (zh) 2017-04-19
AU2015289805B2 (en) 2020-06-25
US11787853B2 (en) 2023-10-17
JP2023052268A (ja) 2023-04-11
AU2020233635B2 (en) 2024-01-18
AU2024202231A1 (en) 2024-05-02
US10519221B2 (en) 2019-12-31
CN113563462B (zh) 2024-08-13
JP7209754B2 (ja) 2023-01-20
WO2016011035A8 (en) 2016-12-08
EP3169407A4 (en) 2018-04-25
JP2024069341A (ja) 2024-05-21
WO2016011035A3 (en) 2016-03-10
AU2020233635A1 (en) 2020-10-08
MX392761B (es) 2025-03-21
US20240076357A1 (en) 2024-03-07
US10294292B2 (en) 2019-05-21
MX2022006558A (es) 2022-07-11
CN119161468A (zh) 2024-12-20
RU2711932C2 (ru) 2020-01-23
JP7453430B2 (ja) 2024-03-19
EP3169407A2 (en) 2017-05-24
US20170218054A1 (en) 2017-08-03
CA2954780A1 (en) 2016-01-21
AU2015289805A1 (en) 2017-03-02
US20200190169A1 (en) 2020-06-18
RU2739952C2 (ru) 2020-12-30
RU2017104638A3 (es) 2019-07-17
US20220025020A1 (en) 2022-01-27
US20250263470A1 (en) 2025-08-21
JP2017523805A (ja) 2017-08-24
WO2016011035A2 (en) 2016-01-21
JP6837434B2 (ja) 2021-03-03
RU2017104638A (ru) 2018-08-15
CN106573154B (zh) 2021-06-15

Similar Documents

Publication Publication Date Title
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
MX2017000595A (es) Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
MX2016004067A (es) Anticuerpo anti-influenza a neutralizantes y usos de los mismos.
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
HUE049081T2 (hu) GP120 elleni neutralizáló antitestek és alkalmazásuk
LT3390441T (lt) Žmogaus imunodeficito virusą neutralizuojantys antikūnai
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
CL2016002156A1 (es) Anticuerpo que une erbb-2 y erbb-3
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
BR112017009297A2 (pt) anticorpos antifator de complemento c1q humanizados e usos dos mesmos
EP3471767A4 (en) Influenza virus hemagglutinin proteins and uses thereof
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
MX2022001220A (es) Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
MX2016009653A (es) Anticuerpos contra glicoproteina f de virus hendra y nipah.
MX2016010059A (es) Anticuerpos útiles en la inmunización pasiva contra la gripe y composiciones, combinaciones y métodos para utilizarlos.
HUE052595T2 (hu) Veszettség vírust és más lyssavirusokat hatékonyan semlegesítõ antitestek és alkalmazásaik
MX2019007107A (es) Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo.
IL246643B (en) Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome
TH1601001392A (th) วิธีวัดไวรัสไข้หวัดใหญ่ชนิด b